The importance of radiotracer characteristics for diagnosis of coronary artery disease (CAD). FlyrcadoTM (F-18 flurpiridaz) 

The significant clinical and economic burden of CAD highlights the need for accurate and timely diagnosis. Current imaging methods present challenges and limitations that can potentially lead to inconclusive or false results, thereby impacting diagnosis and downstream healthcare resource utilization. 

This webinar will provide a comprehensive overview of current CAD diagnostic imaging, describe the burden of disease, and illustrate limitations and unmet needs posed by existing Myocardial Perfusion Imaging (MPI) modalities in the United States. 

The webinar will then introduce FlyrcadoTM (F-18 flurpiridaz), a recent FDA approved PET-MPI radiotracer indicated to diagnose coronary artery disease (CAD) and discuss how FlyrcadoTM may play a role in optimizing the diagnosis of CAD in some difficult-to-image patient subgroups. 

An AMCP Member Webinar

Join AMCP Government Affairs staff for a discussion of the policy priorities of President Trump and the 119th Congress. This session will cover changes of key Congressional and administration policymakers as well as important issues such as pharmacy benefit manager (PBM) reform, drug patent reform, and Medicare, including the ongoing Inflation Reduction Act implementation. With a Republican trifecta in Washington, legislation and regulation may move very quickly. Join us to stay ahead of the most important policy questions for managed care.

This webinar is sponsored by Phizer

Please note that this session is not accredited for continuing pharmacy education credit.

The presentation will discuss LITFULO, ritlecitinib, indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

A Science & Innovation Webinar, presented by Abbvie.

Treatment targets are dynamic, changing with our growing understanding of a disease and the emergence of potent therapies that enhance care standards. Newer mechanisms of action have extended rigorous goal attainment including minimal disease activity (MDA) in psoriatic arthritis, clear or almost clear skin in psoriasis, and endoscopic remission in Crohn’s Disease. The benefits of achieving high treatment targets are now strong enough for medical guidelines to advocate for earlier use of targeted immunomodulators for certain conditions. In budget constrained environments, payers need to understand how innovations are driving demand for newer mechanisms of action in the TIMs marketplace.   

Inflammatory Bowel Disease (IBD) is a chronic, progressive disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability. The American Gastroenterological Association treatment guidelines for the treatment of ulcerative colitis have recently been updated and new living approach to the guidelines, along with a focus on long-term clinical and endoscopic goals for disease management have been established.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

The study drug for the 2025 P&T Competition is VELSIPITY™ (etrasimod). Velsipity is a sphingosine 1-phosphate receptor modulator indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults. This webinar provides an overview of the competition drug for participants.

The deadline for entries to the 2025 National P&T Competition (one entry per pharmacy school) is 11:59 pm EST on Monday, January 20, 2025.

Link to Webinar Coming Soon.